{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:45Z","timestamp":1779322725916,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06416-9","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T21:30:53Z","timestamp":1747863053000},"page":"3091-3101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation"],"prefix":"10.1007","volume":"104","author":[{"given":"Carol Yuk Man","family":"Cheung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung Yin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie","family":"Kho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Kuen","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June Sze Man","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shek Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien Wai Man","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond Siu Ming","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yok Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"6","key":"6416_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H (2020) Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95(6):691\u2013709","journal-title":"Am J Hematol"},{"issue":"Suppl 4","key":"6416_CR2","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","volume":"9","author":"E Nicholson","year":"2009","unstructured":"Nicholson E, Holyoake T (2009) The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma 9(Suppl 4):S376\u2013381","journal-title":"Clin Lymphoma Myeloma"},{"key":"6416_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW et al (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857","journal-title":"J Clin Oncol"},{"key":"6416_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984","journal-title":"Leukemia"},{"key":"6416_CR5","volume-title":"Iclusig (ponatinib) [prescribing information]","author":"ARIAD Pharmaceuticals","year":"2022","unstructured":"ARIAD Pharmaceuticals (2022) Iclusig (ponatinib) [prescribing information]. ARIAD Pharmaceuticals Inc, Cambridge"},{"key":"6416_CR6","unstructured":"Novartis Pharmaceuticals Tasigna (nilotinib) [prescribing information]. East Hanover: Novartis Pharmaceuticals, Inc.; Revised 2024. Accessed on 23 Nov 2024."},{"key":"6416_CR7","volume-title":"Sprycel (dasatinib) [prescribing information]","author":"Bristol Myers Squibb","year":"2021","unstructured":"Bristol Myers Squibb (2021) Sprycel (dasatinib) [prescribing information]. Bristol Myers Squibb, Princeton"},{"key":"6416_CR8","volume-title":"Bosulif (bosutinib) [prescribing information]","author":"Pfzer Inc","year":"2021","unstructured":"Pfzer Inc (2021) Bosulif (bosutinib) [prescribing information]. Pfzer Inc, New York"},{"key":"6416_CR9","volume-title":"Gleevec (imatinib) [prescribing information]","author":"Novartis Pharmaceuticals","year":"2022","unstructured":"Novartis Pharmaceuticals (2022) Gleevec (imatinib) [prescribing information]. Novartis Pharmaceuticals, Inc., East Hanover. Accessed on 23 Nov 2024"},{"key":"6416_CR10","unstructured":"Novartis Pharmaceuticals Scemblix (asciminib) [prescribing information]. East Hanover: Novartis Pharmaceuticals, Inc.; Revised 2021. Accessed on 05 Dec 2024."},{"key":"6416_CR11","unstructured":"Shah NP, Bhatia R, Altman JK et al Chronic Myeloid Leukemia, Version 3.2025 \u2014 November 27, 2024, NCCN Clinical Practice Guidelines in Oncology. Available at https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1427. Accessed on 14 April 2025"},{"key":"6416_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/JBM.S382090","volume":"14","author":"I Rinaldi","year":"2023","unstructured":"Rinaldi I, Winston K (2023) Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review. J Blood Med 14:261\u2013277","journal-title":"J Blood Med"},{"key":"6416_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.16971","volume":"191","author":"G Smith","year":"2020","unstructured":"Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J et al (2020) A British society for haematology guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol 191:171\u2013193","journal-title":"Br J Haematol"},{"issue":"suppl4","key":"6416_CR14","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","volume":"28","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Saussele S, Rosti G et al (2017) Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl4):iv41\u2013iv51","journal-title":"Ann Oncol"},{"issue":"1","key":"6416_CR15","doi-asserted-by":"publisher","first-page":"e237116","DOI":"10.6004\/jnccn.2023.7116","volume":"22","author":"FG Haddad","year":"2024","unstructured":"Haddad FG, Kantarjian H (2024) Navigating the management of chronic phase CML in the era of generic BCR::ABL1 tyrosine kinase inhibitors. J Natl Compr Canc Netw 22(1):e237116","journal-title":"J Natl Compr Canc Netw"},{"key":"6416_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OTT.S289306","volume":"15","author":"S De Santis","year":"2022","unstructured":"De Santis S, Monaldi C, Mancini M et al (2022) Overcoming resistance to kinase inhibitors: the paradigm of chronic myeloid leukemia. Onco Targets Ther 15:103\u2013116","journal-title":"Onco Targets Ther"},{"key":"6416_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/CMAR.S353374","volume":"15","author":"N Hijiya","year":"2023","unstructured":"Hijiya N, Mauro MJ (2023) Asciminib in the treatment of Philadelphia Chromosome-Positive chronic myeloid leukemia: focus on patient selection and outcomes. Cancer Manag Res 15:873\u2013891","journal-title":"Cancer Manag Res"},{"issue":"2","key":"6416_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.36469\/jheor.2022.36976","volume":"9","author":"EL Atallah","year":"2022","unstructured":"Atallah EL, Maegawa R, Latremouille-Viau D et al (2022) Chronic myeloid leukemia: part II-cost of care among patients in advanced phases or later lines of therapy in chronic phase in the united States from a commercial perspective. J Health Econ Outcomes Res 9(2):30\u201336","journal-title":"J Health Econ Outcomes Res"},{"issue":"8","key":"6416_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2217\/cer-2022-0032","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Chen W, Pathak A et al (2022) Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review. J Comp Eff Res 11(8):621\u2013637","journal-title":"J Comp Eff Res"},{"issue":"6","key":"6416_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","volume":"15","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Cortes J (2015) Use of Second- and Third-Generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 15(6):323\u2013334","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"6416_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","volume":"39","author":"JH Lipton","year":"2015","unstructured":"Lipton JH, Bryden P, Sidhu MK et al (2015) Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Leuk Res 39(1):58\u201364","journal-title":"Leuk Res"},{"issue":"1","key":"6416_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","volume":"126","author":"K Naqvi","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J et al (2020) Long-term follow-up of lower dose dasatinib (50\u00a0mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67\u201375","journal-title":"Cancer"},{"issue":"25","key":"6416_CR23","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019brien S et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after Imatinib failure. J Clin Oncol 25(25):3908\u20133914","journal-title":"J Clin Oncol"},{"key":"6416_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Breccia M, Saglio G et al (2020) Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia 34:1495\u20131502","journal-title":"Leukemia"},{"issue":"21","key":"6416_CR25","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O\u2019Brien S et al (2015) Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894\u20133904","journal-title":"Cancer"},{"key":"6416_CR26","unstructured":"Ponatinib SPC (2024) Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/iclusig-epar-product-information_en.pdf. Accessed on 11 July"},{"issue":"20","key":"6416_CR27","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O\u2019Brien S et al (2009) The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114(20):4361\u20134368","journal-title":"Blood"},{"key":"6416_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.6061\/clinics\/2015(08)04","volume":"70","author":"BF Ribeiro","year":"2015","unstructured":"Ribeiro BF, Miranda EC, Albuquerque DM et al (2015) Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors\u2013a single center experience. Clin (Sao Paulo) 70:550\u2013555","journal-title":"Clin (Sao Paulo)"},{"issue":"4","key":"6416_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","volume":"38","author":"S Claudiani","year":"2024","unstructured":"Claudiani S, Chughtai F, Khan A et al (2024) Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance. Leukemia 38(4):796\u2013802","journal-title":"Leukemia"},{"key":"6416_CR30","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1182\/blood.V126.23.4051.4051","volume":"126","author":"E Lomaia","year":"2015","unstructured":"Lomaia E, Zaritskey A, Shuvaev V, Martynkevich I, Fominykh M, Ovsyannikova E et al (2015) Efficacy of tyrosine kinase inhibitors in third line therapy in chronic phase chronic myeloid leukemia. Blood 126:4051","journal-title":"Blood"},{"key":"6416_CR31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2010.110","volume":"24","author":"FJ Giles","year":"2010","unstructured":"Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A et al (2010) Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of Imatinib and dasatinib therapy. Leukemia 24:1299\u20131301","journal-title":"Leukemia"},{"key":"6416_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/10245332.2017.1385193","volume":"23","author":"S Ongoren","year":"2018","unstructured":"Ongoren S, Eskazan AE, Suzan V et al (2018) Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology 23:212\u2013220","journal-title":"Hematology"},{"key":"6416_CR33","doi-asserted-by":"publisher","first-page":"204062072211503","DOI":"10.1177\/20406207221150305","volume":"14","author":"E Atallah","year":"2023","unstructured":"Atallah E, Saini L, Maegawa R et al (2023) Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with \u2a7e2 tyrosine kinase inhibitors: a systematic literature review. Ther Adv Hematol 14:20406207221150305","journal-title":"Ther Adv Hematol"},{"key":"6416_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2018) Ponatinib efficacy and safety in Philadelphia chromosome\u2009\u2013\u2009positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132:393\u2013404","journal-title":"Blood"},{"issue":"21","key":"6416_CR35","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C et al (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031\u20132041","journal-title":"Blood"},{"issue":"3","key":"6416_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C et al (2023) Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37(3):617\u2013626","journal-title":"Leukemia"},{"key":"6416_CR37","doi-asserted-by":"publisher","first-page":"106674","DOI":"10.1016\/j.leukres.2021.106674","volume":"111","author":"CE Ma","year":"2021","unstructured":"Ma CE, Ghosh S, Leyshon C et al (2021) Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI. Leuk Res 111:106674","journal-title":"Leuk Res"},{"key":"6416_CR38","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE et al (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 381:2315\u20132326","journal-title":"N Engl J Med"},{"issue":"3","key":"6416_CR39","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/bjh.18323","volume":"199","author":"N Shanmuganathan","year":"2022","unstructured":"Shanmuganathan N, Hughes TP (2022) Asciminib for chronic myeloid leukaemia: next questions. Br J Haematol 199(3):322\u2013331","journal-title":"Br J Haematol"},{"issue":"1","key":"6416_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/hematology.2022000328","volume":"2022","author":"TP Hughes","year":"2022","unstructured":"Hughes TP, Shannuganathan (2022) Management of TKI - resistant chronic phase CML. Hematol Am Soc Hematol Educ Program 2022(1):129\u2013137","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"6416_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ajhp\/zxac286","volume":"80","author":"S Monestime","year":"2023","unstructured":"Monestime S, Al Sagheer T, Tadros M (2023) Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation. Am J Health Syst Pharm 80(2):36\u201343","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"6416_CR42","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/cancers15041045","volume":"15","author":"L P\u00e9rez-Lamas","year":"2023","unstructured":"P\u00e9rez-Lamas L, Luna A, Boque C et al (2023) Toxicity of asciminib in real clinical practice: analysis of side effects and cross-toxicity with tyrosine kinase inhibitors. Cancers (Basel) 15(4):1045","journal-title":"Cancers (Basel)"},{"key":"6416_CR43","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley JF, Lomaia E et al (2021) Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138:2042\u20132050","journal-title":"Blood"},{"issue":"1","key":"6416_CR44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1182\/hematology.2022000329","volume":"2022","author":"C Niederwieser","year":"2022","unstructured":"Niederwieser C, Kr\u00f6ger N (2022) Transplantation in CML in the TKI era: who, when, and how? Hematol Am Soc Hematol Educ Program 2022(1):114\u2013122","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"6416_CR45","doi-asserted-by":"publisher","first-page":"642005","DOI":"10.3389\/fonc.2021.642005","volume":"11","author":"F Castagnetti","year":"2021","unstructured":"Castagnetti F, Pane F, Rosti G et al (2021) Dosing strategies for improving the Risk-Benefit profile of Ponatinib in patients with chronic myeloid leukemia in chronic phase. Front Oncol 11:642005","journal-title":"Front Oncol"},{"issue":"3","key":"6416_CR46","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000501927","volume":"143","author":"S Saussele","year":"2020","unstructured":"Saussele S, Haverkamp W, Lang F et al (2020) Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia Chromosome-Positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management. Acta Haematol 143(3):217\u2013223","journal-title":"Acta Haematol"},{"key":"6416_CR47","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","volume":"38","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Apperley J, Cortes J et al (2024) Dose modification dynamics of Ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38:475\u2013481","journal-title":"Leukemia"},{"key":"6416_CR48","doi-asserted-by":"publisher","first-page":"1036437","DOI":"10.3389\/fonc.2022.1036437","volume":"12","author":"H Qian","year":"2022","unstructured":"Qian H, Gang D, He X, Jiang S (2022) A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia. Front Oncol 12:1036437","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"6416_CR49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2022-170698","volume":"140","author":"Z Qian Jiang","year":"2022","unstructured":"Qian Jiang Z, Li Y, Hou et al (2022) Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-Resistant chronic- and Accelerated-Phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation. Blood 140(Supplement 1):203\u2013204","journal-title":"Blood"},{"issue":"Supplement 1","key":"6416_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2020-139847","volume":"136","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Saikia T, Kim DW et al (2020) Phase 1 trial of Vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): activity in CML chronic phase patients failing TKI therapies including Ponatinib. Blood 136(Supplement 1):51\u201352","journal-title":"Blood"},{"key":"6416_CR51","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/S2352-3026(24)00354-5","volume":"12","author":"JE Cortes","year":"2025","unstructured":"Cortes JE, Kim DW, Saikia T et al (2025) Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1\/2 trial. Lancet Haematol 12:e201\u2013e13","journal-title":"Lancet Haematol"},{"key":"6416_CR52","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3324\/haematol.2011.052571","volume":"96","author":"AM Carella","year":"2011","unstructured":"Carella AM, Goldman JM, Martinelli G et al (2011) Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica 96:1737\u20131739","journal-title":"Haematologica"},{"issue":"1","key":"6416_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.hemonc.2021.02.003","volume":"15","author":"F Yassine","year":"2022","unstructured":"Yassine F, Reljic T, Moustafa MA et al (2022) Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. Hematol Oncol Stem Cell Ther 15(1):36\u201343","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"15","key":"6416_CR54","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim DW et al (2017) Overall survival with Ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123(15):2875\u20132880","journal-title":"Cancer"},{"issue":"11","key":"6416_CR55","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41409-019-0513-5","volume":"54","author":"A L\u00fcbking","year":"2019","unstructured":"L\u00fcbking A, Dreimane A, Sandin F et al (2019) Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transpl 54(11):1764\u20131774","journal-title":"Bone Marrow Transpl"},{"key":"6416_CR56","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41409-021-01472-x","volume":"57","author":"S Masouridi-Levrat","year":"2022","unstructured":"Masouridi-Levrat S, Olavarria E, Iacobelli S et al (2022) Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the chronic malignancy working party of the EBMT. Bone Marrow Transpl 57:23\u201330","journal-title":"Bone Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06416-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06416-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06416-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:27:16Z","timestamp":1757183236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06416-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6416"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06416-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Dr Raymond Siu Ming Wong has received research support and speaker honoraria from Novartis, Bristol Myers Squibb and Pfizer, and is a member of a research steering committee for Novartis, with honorarium. All other authors have declared no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}